Form 4 for EW Edwards Lifesciences
Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-16 · accession 0001225208-23-002275 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-17 | 2023-02-16 | EW | Ullem Scott B. | CFO, CVP | A - Grant | $0.00 | +1,941 | 18.1K | +12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-16 | A | A | 1,941 | $0.00 | 18,119 | D | — | — | (F1) These restricted stock units were granted on February 16, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |